UnknownEarly Phase 1NCT05263817
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
Studying Hereditary amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhejiang University
- Principal Investigator
- He Huang, PhDFirst Affiliated Hospital of Zhejiang University
- Intervention
- CD19/BCMA CAR T-cells(biological)
- Enrollment
- 75 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Collaborators
Yake Biotechnology Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05263817 on ClinicalTrials.govOther trials for Hereditary amyloidosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06672237A Phase 3 Study of NTLA-2001 in ATTRv-PNIntellia Therapeutics
- ENROLLING BY INVITATIONNCT07124377Phenotypic Manifestations of Hereditary ATTR AmyloidosisHospital 9 de Julio de Las Breñas
- RECRUITINGNCT06251778NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on TafamidisPaolo Milani
- RECRUITINGPHASE2NCT05758493Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic AmyloidosisOregon Health and Science University